Disturbing intracellular replication of Helicobacter pylori by sorafenib treatment in-vitro
Roshdy, T., Saleh, S., Abass, N., Bassiouny, K., Khalil, H. (2021). Disturbing intracellular replication of Helicobacter pylori by sorafenib treatment in-vitro. EKB Journal Management System, 17(1), 285-295. doi: 10.21608/ajbs.2021.212175
Tamer Mohammed Roshdy; Shimaa A. Saleh; Nasser H. Abass; Khalid Bassiouny; Hany Khalil. "Disturbing intracellular replication of Helicobacter pylori by sorafenib treatment in-vitro". EKB Journal Management System, 17, 1, 2021, 285-295. doi: 10.21608/ajbs.2021.212175
Roshdy, T., Saleh, S., Abass, N., Bassiouny, K., Khalil, H. (2021). 'Disturbing intracellular replication of Helicobacter pylori by sorafenib treatment in-vitro', EKB Journal Management System, 17(1), pp. 285-295. doi: 10.21608/ajbs.2021.212175
Roshdy, T., Saleh, S., Abass, N., Bassiouny, K., Khalil, H. Disturbing intracellular replication of Helicobacter pylori by sorafenib treatment in-vitro. EKB Journal Management System, 2021; 17(1): 285-295. doi: 10.21608/ajbs.2021.212175

Disturbing intracellular replication of Helicobacter pylori by sorafenib treatment in-vitro

African Journal of Biological Sciences
Article 21, Volume 17, Issue 1, 2021, Page 285-295  XML PDF (617.55 K)
Document Type: Original Article
DOI: 10.21608/ajbs.2021.212175
View on SCiNiTO View on SCiNiTO
Authors
Tamer Mohammed Roshdy email 1; Shimaa A. Saleh2; Nasser H. Abass2; Khalid Bassiouny2; Hany Khalil2
1Department of Molecular Biology, Genetic Engineering and Biotechnology research institute, University of Sadat City, Egypt
2Department of Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Egypt
Abstract
Helicobacter pylori (H. pylori) is a Gram-negative, spiraling, microaerophilic bacteria that normally infect the stomach of human and produces stomach inflammation which can develop to gastric ulcers of the stomach or the upper part of the small intestine. Several cellular signaling pathways such as mitogen activated protein kinases (MAPKs) and RNA activating factor 1 (RAF-1) signaling cascade may be involved in H. Pylori infection. MAPKs are a type of extracellular communication that consists of a chain of proteins that extends from cell receptors to nuclear DNA. MAPK signaling is usually triggered by cell receptors attaching to epidermal growth factors (EGF), also known as the growth factor pathway or extracellular signal-regulated kinase (ERK). By administering HeLa cells with Sorafenib (SOR), a systemic medication for malignant malignancies, we studied the possibility of inhibiting H. pylori replication. In pre-treated and infected cells, the expression of RAF-1 and autophagy related 5 (Atg5) was monitored to see if targeting these factors can disrupt H. Pylori intracellular replication.  Surprisingly, the relative expression of bacterial 16s ribosomal RNA in SOR-treated cells revealed a competitive suppression of bacterial replication (16srRNA). Furthermore, SOR therapy successfully controlled the expression of the Raf-1 and Atg5 genes without causing any toxicity. In addition, SOR therapy lowered the production of tumor necrosis factor (TNF-) in a dose and time-dependent manner. These data suggest that SOR can disrupt H. Pylori replication in HeLa cells by suppressing MAPK and autophagy signaling, with minimal TNF- generation from treated cells.
Keywords
Helicobacter pylori; sorafenib; HeLa cell; MAPK signaling and autophagic process
Statistics
Article View: 201
PDF Download: 166